SC
CLDX icon

Stephens Consulting’s Celldex Therapeutics CLDX Stock Holding History

Stephens Consulting’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-20
Closed -$363 – 1351
2025
Q1 		$363 Buy
+20
New +$447 ﹤0.01% 1246

Other funds holding CLDX

KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Stephens Consulting's CLDX Position: Q2 2025 in Review

Stephens Consulting sold out of Celldex Therapeutics (CLDX) in Q2 2025, closing a stake of 20 shares — an estimated $363 sold.

Stephens Consulting first reported a position in CLDX in Q1 2025 and held it in 1 quarter. The position peaked at $363 in Q1 2025. 180 funds tracked by Wall St. Rank hold CLDX as of Q2 2025.

  • Stephens Consulting reported no remaining Celldex Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Stephens Consulting sold 20 Celldex Therapeutics shares in Q2 2025, an estimated $363.
  • Stephens Consulting first reported a position in Celldex Therapeutics in Q1 2025 and held it in 1 quarter.
  • Stephens Consulting's Celldex Therapeutics position peaked at $363 in Q1 2025.
  • 180 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2025.

Based on Stephens Consulting's 13F filing for Q2 2025, filed 25 Jul 2025.